A conservative 3% trend means a $100 billion Medicare Advantage book could face a $3 billion shortfall. Even before the Final ...
In today’s Pharma Pulse, UK regulators seize thousands of fake weight loss pens, while new data reveals that the "miracle jab" is financially out of reach for nearly 70% of users.
In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while ...
In today’s Pharma Pulse, Eli Lilly launches the monthly Zepbound KwikPen to streamline obesity care, while Gilead Sciences moves to acquires Arcellx in a massive expansion of its cell therapy ...
In a recent discussion, John Stanford, executive director at Incubate,reacted to the Centers for Medicare & Medicaid Services’ (CMS) decision to expand Medicare drug price negot ...
Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...
In today’s Pharma Pulse, BioNTech escalates its patent battle against Moderna over next-gen COVID shots, while a new ...
The FDA’s Plausible Mechanism Framework is designed to facilitate the approval of highly individualized therapies for patients with ultra-rare diseases. The Supreme Court invalidated IEEPA-based ...
Patients want pills. We see this in the GLP-1 space. Everything should actually be flowing money towards pills, because payers are also quicker to reward pills. Yet the money is going exactly in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results